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Background: The aim of this multicenter study was to investigate the relationship between
single nucleotide polymorphisms (SNPs) of the cyclooxygenase-2 (COX2) gene and susceptibility
to sarcoidosis, as well as the relation between these SNPs and the evolution of the disease.
Material and methods: This multicenter investigation involved seven hospitals in Spain. We
used a caseecontrol design followed by a prospective follow-up study. Sarcoid patients were
recruited from the participating institutions during outpatient routine visits. Age- and
gender-matched control subjects were recruited mainly from among outpatients attending
the participating hospitals. Four SNPs in the COX2 gene (COX2.5909 T > G, COX2.8473 T >
C, COX2.926 G > C, and COX2.3050 G > C) were genotyped using fluorescent hybridization
probes among 131 patients with sarcoidosis (63 males; mean age: 47  15 years) and 157
healthy controls (83 males; mean age: 50  16 years). We employed a binomial multiple
logistic regression analysis to test the association between the selected SNPs and disease
susceptibility. The clinical, functional and radiological prognosis of the sarcoidosis patientsrsitario Virgen del Rocı´o, Avda Manuel Siurot s/n, 41013 Seville, Spain. Tel.: þ34 955013164; fax: þ34
(J.L. Lopez-Campos).
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428 J.L. Lopez-Campos et al.was determined after a mean follow-up of 37.4  30.4 months.
Results: Carriers of the homozygous CC genotype of the COX2.8473 T > C polymorphism had a
higher risk of sarcoidosis compared with TT carriers (OR: 3.08; 95% CI: 1.2e7.7; p Z 0.035).
84% of patients achieved improvement or complete remission at follow-up. No association
between the investigated SNPs and prognosis was seen.
Conclusions: Our data suggest that the homozygous CC genotype of the COX2.8473 T > C poly-
morphism may be associated with sarcoidosis susceptibility. No significant association with
prognosis was detected.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a multi-systemic granulomatous disease of
unknown aetiology that primarily affects the lung and
lymphatic systems.1 Sarcoidosis has a multifactorial origin
that includes genetic predisposition, infectious organisms
and environmental exposures as probable underlying
mechanisms. Specifically, it has been hypothesized that the
disease occurs when a genetically susceptible host is
exposed to a specific environmental antigen. In this
context, an exaggerated inflammatory response takes
place, characterized by large numbers of activated
macrophages and T lymphocytes bearing the CD4 helper
phenotype, with a pattern of cytokine production consis-
tent with a Th1-type immune response.2
Prostaglandin E2 (PGE2), a member of the eicosanoid
family of arachidonic acid derivatives,3,4 has been impli-
cated in the pathogenesis of several interstitial lung
diseases. Cyclooxygenase (COX) plays a key regulatory role
in PGE2 synthesis and occurs in both constitutive (COX1) and
inducible (COX2) isoforms.5 A reduced COX2 expression in
cultured lung fibroblasts isolated from patients with idio-
pathic pulmonary fibrosis has been reported.6 Moreover, an
increased propensity for pulmonary fibrosis has been
observed in COX2edeficient mice.7
A reduced COX2 expression in bronchiolar epithelial cells
and macrophages of sarcoid patients has been reported.8
Genetic variants in the COX2 gene can alter enzyme func-
tion and contribute to an individual’s inflammatory
response, thereby potentially modifying the susceptibility
and clinical course of sarcoidosis.9 We therefore investi-
gated the association between four single nucleotide
polymorphisms (SNPs) of the COX2 gene and susceptibility
to sarcoidosis, as well as the relation between these SNPs
and the evolution of the disease.
Methods
This multicenter investigation involved seven hospitals in
Spain. We used a caseecontrol design followed by
a prospective follow-up study. The study protocol was
approved by our Institution Review Board, and written
informed consent was obtained from all participants.
Subjects
Sarcoid patients were recruited from the participating
institutions during outpatient routine visits. The diagnosisof sarcoidosis was established according to the interna-
tional consensus statement.1 Histologic detection of non-
caseating granulomas in biopsy specimens was required to
include patients. We also accepted a diagnosis without
a biopsy specimen in the presence of typical clinicoradio-
logic findings and evidence of lymphocytic alveolitis with an
elevated CD4/CD8 ratio (>3.5) on bronchoalveolar
lavage.10 Patients with a history of malignancy were
excluded from our study.
Age- and gender-matched control subjects were adult
men and women who had attained their 18th birthday
at the time of enrollment, had not a diagnosis of
sarcoidosis, and were unrelated by blood to patients
enrolled in the study. Control subjects were recruited
mainly from among outpatients attending the partici-
pating hospitals for respiratory disorders other than
granulomatous lung diseases, extrinsic allergic alveoli-
tis, fungal infections or cancer. All patients and controls
were Caucasian whites ascertained to be of Spanish
descent.
The following data were collected in all participants at
the time of diagnosis: age, gender, age at onset, date of
diagnosis, type of biopsy (transbronchial, thoracotomy,
video-assisted thoracoscopy, mediastinoscopy, others),
pulmonary function tests, laboratory tests, serum angio-
tensin converting enzyme (ACE) levels, and initial radio-
logical stage.
All patients were followed-up from their initial presen-
tation to evaluate the severity and progression of disease.
Disease progression was classified as follows: complete
remission (no symptoms, no radiological abnormalities, and
normal lung function), persistence of the disease with
improvement (change from a higher to a lower radiological
stage or proven reduction in the severity of radiological
alterations within the same stage, and/or improvement in
lung function parameters with an FVC > 15% or a KCO >
20%), or persistent progressive disease (change from
a lower to a higher radiological stage or proven increase of
radiological alterations within the same stage, and/or
worsening in lung function parameters with an FVC < 15% or
a KCO < 20%).
The radiological staging was performed by computed
tomography according to the international statement1
employing the widely accepted classification of Siltzbach
et al.11 Pulmonary function tests included spirometry,
blood gas analysis, total lung capacity, and diffusing
capacity according to international guidelines.12e14 All
pulmonary function test results were expressed as percent
of predicted value and as absolute value.
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COX2 polymorphisms in sarcoidosis 429T P C C C CSNP selection and genotyping
Although several SNPs in the COX2 gene have been
described,15 the majority of genetic association studies
published thus far have tended to type only a few poly-
morphisms that are regarded as candidates because of their
functional importance. The COX2.926 polymorphism in the
promoter region has been implicated in transcription
alteration of the COX2 gene and an increase in the levels of
C-reactive protein. Since COX2 polymorphisms have not
been extensively studied, we have also selected the other
three SNPs of this gene with appreciable frequency in
Caucasian populations which covered the entire length of
the gene, i.e. COX2.3050 (exon 3), COX2.5209 (intron 5)
and COX2.8473 (exon 10, 30-UTR region). Overall, a total
four single nucleotide polymorphisms in COX2 were geno-
typed, namely COX2.5209 T > G, COX2.8473 T > C,
COX2.926 G > C (rs20417), and COX2.3050 G > C.
Genomic DNA was extracted from peripheral blood
leukocytes with the High Pure PCR Template Preparation
Kit (Roche Diagnostics, Mannheim, Germany) according to
the manufacturer’s recommendations. Four SNPs in COX2
were genotyped: COX2.926 G > C (rs20417), COX2.3050 G >
C (rs5277), COX2.5209 T > G (rs20432), and COX2.8473 T >
C (rs5275). Genomic DNA was amplified by conventional
PCR. PCR reaction mix consisted of 1  PCR buffer (Euro-
Clone, Celbio, Milan, Italy), 2 mM MgCl2, 0.4 mM of each
primer, 0.15 mM of each dNTP, 1.5 U of Euro Taq DNA
polymerase (EuroClone, Celbio, Milan, Italy), 5 mL of total
DNA and water to a total volume of 25 mL. The reactions
were performed on a MyCycler thermal cycler (Bio-Rad
Laboratories, Inc., Hercules, CA, USA) and amplifications
conditions comprised 30 cycles of 15 s at 94, 10 s at 55,
and 20 s at 72. Polymorphisms were detected using
hybridization probes and fluorescent melting curves16 with
the LightCycler System (Roche Molecular Biochemicals).
Probes and primers sequences are described in Table 1.Statistical analysis
Continuous variables are presented as the mean  SD and
qualitative variables as the absolute and relative frequen-
cies. For binary variables, statistically significant differ-
ences between group proportions were evaluated using the
c2 test or Fisher’s exact test, as appropriate. To adjust for
multiple comparisons, the Bonferroni’s correction was
applied for all significant polymorphisms. The Hardye
Weinberg equilibrium for all polymorphisms in each group
was tested by using the c2 test. We compared groups using
the unpaired Student’s t-test for normally distributed
variables after correction for equality of variance (Levene’s
test). Binomial multiple logistic regression analysis was
used to examine the relationship between genotypes and
disease risk, with the presence of sarcoidosis as a binary
outcome variable after adjustment for age and gender.
Results are presented as adjusted odds ratios (ORs) and 95%
confidence intervals (CIs). Quantitative data before and
after the follow-up period were compared by paired t-test.
Cox proportional hazards model was used to examine the
relationship between genotypes and disease prognosis. For
the purpose of this analysis, binary outcome measures
Table 2 Functional characteristics of sarcoid patients at baseline.
Variable Entire cohort
(nZ 131)
Stage 0
(nZ 9)
Stage 1
(nZ 42)
Stage 2
(nZ 63)
Stage 3
(nZ 14)
Stage 4
(nZ 3)
ACE (IU/L) 72 36 55 30.8 63.3 26.7 79.8 42 63.9 30.5 87.2 16.7
FVC (%) 89 19 100.1 19.1 91.5 18.6 88.9 13.9 88.5 17.4 66.4 12.6
FEV1 (%) 86 19 98.4 22.6 89 18.4 84.9 20.4 89.5 18.1 67.9 21
FEV1/FVC (%) 80 9 79.8 6.1 80.5 6.6 79.3 10.6 83.6 8 81.3 6.4
TLC (%) 87 14 91.6 5.3 89.6 14 87.5 16 83.4 7.5 68.9 14.2
KCO (%) 104 24 118.6 10.4 106.4 28.7 100.1 23.7 114.6 19.3 80.8 9.8
PaO2 (mmHg) 82 12 85 4.2 85.4 13.7 81.1 13.2 81.7 9.2 70.6 3
ACE: angiotensin-converting enzyme; FVC: forced vital capacity; FEV1: forced expiratory volume in on second; TLC: total lung capacity;
KCO: Krogh coefficient; and PaO2: arterial blood oxygen partial pressure.
430 J.L. Lopez-Campos et al.(remission and persistence of the disease with improve-
ment versus persistent progressive disease; persistent
versus non-persistent disease) were used. Statistical anal-
ysis was performed using the Statistical Package for Social
Sciences (SPSS, Inc., Chicago, IL, USA), version 14.0.
A p-value < 0.05 was taken as the level for significance.
Results
General characteristics of the study participants
A total of 131 sarcoid patients (63 males; age: 47  15
years) and 157 controls (83 males; age: 50  16) were
included. The diagnoses on subjects were obtained by
transbronchial biopsy in 55 (42%) cases, bronchial biopsy in
2 (1.5%) cases, thoracotomy in 4 (3.1%) cases, video-assis-
ted thoracoscopy in 12 (9.2%) cases, mediastinoscopy in 21
(16%) cases, and extrathoracic biopsies in 31 (23.7%) cases.Table 3 Distribution of COX2 polymorphisms in the study parti
Polymorphisms Entire cohort
(nZ 288)c
Controls
(nZ 157)c
COX2.926
G/G 160 (55.6%) 94 (59.9%)
G/C 116 (40.3%) 59 (37.6%)
C/C 12 (4.2%) 4 (2.5%)
COX2.3050
G/G 213 (74%) 116 (73.9%)
G/C 69 (24%) 38 (24.2%)
C/C 6 (2.1%) 3 (1.9%)
COX2.5209
T/T 160 (55.6%) 92 (58.6%)
T/G 117 (40.6%) 61 (38.9%)
G/G 11 (3.8%) 4 (2.5%)
COX2.8473
T/T 125 (43.4%) 76 (48.4%)
C/T 139 (48.3%) 73 (46.5%)
C/C 24 (8.3%) 8 (5.1%)
NS: not significant.
a p-Value calculated by c2 test.
b Calculated by binomial multiple logistic regression analysis adjust
c Values expressed as absolute and relative frequencies related toThe extrathoracic biopsy sites included lymph nodes, skin
and liver. In 6 cases a diagnosis of sarcoidosis was admitted
with clinical criteria without a biopsy. The main functional
characteristics of sarcoid patients are summarized in Table
2. The radiological stages were as follows: stage 0 in 9
(6.9%) patients, stage 1 in 42 (32.1%) patients, stage 2 in 63
(48.1%) patients, stage 3 in 14 (10.7%) patients, and stage 4
in 3 (2.3%) patients.
Allele frequencies in sarcoidosis patients
and control subjects
HardyeWeinberg equilibrium analysis revealed that both
cases and controls were under genetic equilibrium at all
the loci tested. The distribution of COX2 genotypes is
presented in Table 3. The distribution of the COX2.8473 C
> T polymorphism was significantly different between
groups by c2 test either without (p Z 0.035) or with thecipants.
Sarcoid patients
(nZ 131)c
pa OR
(95% CI)b
66 (50.4%) NS 1
57 (43.5%) 2.2 (0.7e6.8)
8 (6.1%) 1.7 (0.19e16.2)
97 (74%) NS 1
31 (23.7%) 0.9 (02e3.3)
3 (2.3%) 1.1 (0.2e5.9)
68 (51.9%) NS 1
56 (42.7%) 2.7 (0.8e8.9)
7 (5.3%) 1.7 (0.1e16)
49 (37.4%) 0.035 1
66 (50.4%) 1.7 (0.5e4.9)
16 (12.2%) 3.08 (1.2e7.7)
ing for age and gender.
the number of patients in each column.
Table 4 Progression of the functional characteristics of sarcoid patients according to the progression of the disease.
Variable Complete disease
remission (nZ 55)
Persistent disease
with improvement (nZ 56)
Persistent progressive
disease (nZ 14)
D ACE (UI/L) 15.1 37.6 15.3 39.7 8.8 44.1
D FVC (mL) 27.6 400 30.5 399 80.7 604
D FEV1 (mL) 13.5 339 19.5 86 61.5 422
D FEV1/FVC (%) 0.4 6.4 2.7 8.2 1.6 9.5
D TLC (mL) 194 420 164 612 6 464
D KCO (%) 2.29 16.1 0.6 21.2 6.4 12.8
D PaO2 (mmHg) 10.6 16.8 0.7 13.8 5 7.3
ACE: angiotensin-converting enzyme; FVC: forced vital capacity; FEV1: forced expiratory volume in on second; TLC: total lung capacity;
and KCO: Krogh coefficient. PaO2: arterial blood oxygen partial pressure.
COX2 polymorphisms in sarcoidosis 431application of the Bonferroni’s correction (p Z 0.011).
Carriers of the homozygous CC genotype of the COX2.8473
T > C polymorphism had a higher risk of sarcoidosis
compared with TT carriers (OR: 3.08; 95% CI: 1.2e7.7;
p Z 0.035).
Allele frequencies and prognosis of sarcoidosis
One hundred and twenty-five sarcoid patients were fol-
lowed-up for 37.4  30.4 months. The remaining six
patients were lost to follow-up. As shown in Tables 4 and
5, persistent progressive disease was observed in fourteen
patients (11.2%). A total of 56 patients (44.8%) showed
persistence of the disease with improvement, whereas the
remaining 55 (44.0%) showed a complete disease remis-
sion. There was no association between the investigated
SNPs and disease progression or the persistence of
sarcoidosis.Table 5 Changes in radiological characteristics of sarcoid patie
Radiological stage at baseline Radiological stage at follow-
0 1
Complete disease remission
0 6 (100%)
1 17 (100%)
2 26 (100%)
3 6 (100%)
Total 55 (100%)
Persistent disease with improvement
0 2 (100%)
1 7 (31.8%) 15 (68.2%)
2 4 (16%) 4 (16%)
3
4
Total 13 (23.2%) 19 (33.9%)
Persistent progressive disease
0 1 (100%)
2
3
4
Total 1 (7.1%)
Values are expressed as absolute and relative frequencies related toDiscussion
In the present study, we have aimed to determine whether
COX2 polymorphisms might influence susceptibility to and
prognosis of sarcoidosis. The principal finding of our study is
that the COX2.8473 T > C polymorphism is associated with
susceptibility to sarcoidosis. On the other hand, our data
have revealed no association between the selected SNPs
and disease progression.
Sarcoidosis has a complex pathophysiology involving
both genetic and environmental factors.17e19 Interestingly,
previous studies have shown that prostaglandins have
pathophysiological significance in this condition. For
instance, it has been observed that the expression of COX2
in macrophages and epithelial cells of sarcoidosis speci-
mens is significantly lower than in controls.8 A previous
study has also demonstrated an increased PGF2a/PGE2
ratio in sarcoid patients compared with healthy subjects.20nts according to disease progression.
up
2 3 4 Total
6
17
26
6
55
2
22
17 (68%) 25
2 (33.3%) 4 (66.7%) 6
1 (100%) 1
19 (33.9%) 4 (7.1%) 1 (1.8%) 56
1
5 (55.6%) 1 (11.1%) 3 (33.3%) 9
1 (50%) 1 (50%) 2
2 (100%) 2
5 (35.7%) 2 (14.3%) 6 (42.9%) 14
the total number of patients in each line.
432 J.L. Lopez-Campos et al.In the present report, we observed that the carriage of the
CC genotype of the COX2.8473 T > C gene polymorphism
was associated with an increased risk of sarcoidosis. The
COX2.8473 T > C polymorphism is located at the 30
untranslated region (UTR) of COX2 gene. Given the role of
the 30 UTR in the regulation of mRNA expression,21,22 it is
possible that the COX2.8473 T > C polymorphism may
influence COX2 expression. This possibility would be in
keeping with the findings of Petkova and coworkers, who
found that COX2 expression is significantly decreased in
alveolar macrophages from patients with sarcoidosis.8
In our sample, the association between COX2.926 G > C
polymorphism and susceptibility to sarcoidosis was of
borderline statistical significance. A previous study by Hill
et al.9 has shown an association between this polymorphism
and sarcoidosis in a slightly larger Caucasian sample. The
COX2.926 G > C polymorphism has been shown to be func-
tional, with the C allele having lower promoter activity than
the G allele.9 Notably, previous studies have shown an asso-
ciation between this common genetic variant with ischemic
cardiac and cerebrovascular disease23 and asthma.24 In that
case, with a sufficiently larger sample size, we can expect to
find an association between this polymorphism and sarcoid-
osis even in our Spanish population.
The prognostic implications of COX2 polymorphisms in
sarcoidosis are less clear. In the present study we failed to
find a significant association between the selected SNPs and
patient outcome. Interestingly, Hill and coworkers9 have
recently shown that COX2.926 G > C polymorphism may be
considered as a prognosticmarker in sarcoidosis to predict an
increased risk of poor outcome in a white British population.
In present study we failed to replicate these findings in
a white Spanish sample. We hypothesize that the different
and conflicting patterns of association of COX2 poly-
morphisms and prognosis of sarcoidosis may be explained by
geographic trends. Between ethnic group differences in
COX2 allele and genotype distribution could thus be related
to the different patterns of association between COX2
polymorphisms and sarcoidosis in various European studies.
We also recognize that our sample included only 14 patients
with persistent progressive disease, compared with 76
subjects with persistent disease and 102 participants with
non-persistent disease described by Hill and colleagues.9
Since sarcoidosis can generally be considered as a benign
disease with a good prognosis, we hypothesize that larger
sample sizes than that of this study may be needed to
generate a finding of statistical significance. In any case,
replication in a second cohort of subjects would be highly
desirable in genetic association studies.
In conclusion, the present study reveals that the
COX2.8473 T > C polymorphism is associated with
sarcoidosis susceptibility. These findings reinforce the
concept that COX2 is pathophysiologically involved in
sarcoidosis. Further studies aiming to determine the asso-
ciation and prognostic significance of COX2 SNPs in
sarcoidosis among different ethnic groups are needed.Conflict of interest statement
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